First LSD Study in Humans In Over 35 Years Treats Final Subject

LSD-Assisted Psychotherapy in the Treatment of Anxiety Secondary to Life Threatening Illness

Location: Solothurn, Switzerland

MAPS is proud to sponsor the first study of the therapeutic use of LSD in humans in over 35 years. This study, based in Switzerland, investigates the safety and effectiveness of LSD-assisted psychotherapy in subjects with life-threatening illnesses and who are experiencing associated anxiety. The study received final approval from the BAG (the Swiss DEA) on December 5, 2007, final approval from the Ethics Committee (the Swiss IRB equivalent) on October 30, 2007, and clearance from SwissMedic (the Swiss FDA equivalent) on November 8, 2007. The first subject was enrolled on April 23, 2008, and all subjects have now been treated.

• Dr. Gasser’s MAPS-sponsored LSD/Anxiety protocol
• LSD investigator’s brochure
• Memorandum of Understanding Between MAPS and Dr. Gasser

This study has cost $190,000; all of which has been raised.